Abeona Therapeutics’ (ABEO) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Abeona Therapeutics (NASDAQ:ABEO) in a report released on Monday morning, Marketbeat.com reports. The firm currently has a $15.00 price target on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently commented on ABEO. StockNews.com cut shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 22nd. Oppenheimer started coverage on shares of Abeona Therapeutics in a report on Wednesday, March 5th. They set an “outperform” rating and a $16.00 target price for the company. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $17.50.

Abeona Therapeutics Stock Performance

Shares of NASDAQ ABEO opened at $5.12 on Monday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. The stock has a 50 day moving average price of $5.43 and a 200 day moving average price of $5.83. The stock has a market capitalization of $222.57 million, a PE ratio of -1.90 and a beta of 1.79. Abeona Therapeutics has a 52 week low of $3.05 and a 52 week high of $8.45.

Abeona Therapeutics (NASDAQ:ABEO) last issued its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.19. Analysts predict that Abeona Therapeutics will post -1.16 earnings per share for the current fiscal year.

Institutional Trading of Abeona Therapeutics

Institutional investors have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. acquired a new stake in shares of Abeona Therapeutics in the third quarter valued at approximately $151,000. Citigroup Inc. increased its stake in Abeona Therapeutics by 10.1% during the 3rd quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company’s stock worth $3,897,000 after acquiring an additional 56,332 shares during the period. Western Standard LLC raised its holdings in Abeona Therapeutics by 7.0% in the 3rd quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock valued at $10,732,000 after acquiring an additional 110,998 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Abeona Therapeutics during the 3rd quarter valued at $84,000. Finally, XTX Topco Ltd acquired a new stake in shares of Abeona Therapeutics during the 3rd quarter worth $160,000. Institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.